Retrospective/Prospective Data Collection on the LDR ROIA Interbody Fusion Device With VerteBRIDGE Plating

NCT ID: NCT02104141

Last Updated: 2019-04-24

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

51 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-30

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this combination retrospective and prospective post market study is to examine the short term safety and efficacy of the ROI-A® interbody fusion device with VerteBRIDGE® plates to treat single and two-level degenerative disc disease between L2 and S1, with a focus on fusion rates and patient outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Degenerative Disc Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Operated Subjects

ROIA Interbody Cage with VerteBRIDGE plating

ROIA Interbody Cage with VerteBRIDGE plating

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ROIA Interbody Cage with VerteBRIDGE plating

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must have degenerative disc disease (DDD) of the lumbar spine between L2 and S1
* Subjects may have up to a Grade 1 spondylolisthesis at the involved level(s)
* Subject must have the ROI-A® device at one level or at two contiguous levels between L2 and S1 only
* Subject should have had a minimum of 6 months non-surgical treatment prior to receiving the ROI-A® device
* Subject may have had NO MORE THAN two previous non-fusion surgeries to the lumbar spine at the same levels as the ROI-A®
* Subject must be at least 21 years of age at the time of surgery
* Subject must be willing to signed an informed consent document and return for a 12 month visit

Exclusion Criteria

* Subject had more than Grade 1 spondylolisthesis at the operated level
* Subject is a prisoner.
* Subject was pregnant at the time of surgery.
* Subject had an active infection or sepsis at the time of surgery.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

LDR Spine USA

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ROIA100

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

LUMBAR & SACROILIAC FUSION STUDY
NCT07204288 RECRUITING NA
OLIF25™ /OLIF51™ Study
NCT02657421 TERMINATED